Baltimore plays a losing economic development hand

Economic development officials in Baltimore are fretting that they're one step behind the pace being set in Montgomery County, where low-cost lab space along with offers of small loans and grants have been luring away emerging drug developers. In the case of Amulet Pharmaceuticals, a spinoff of Johns Hopkins, a $25,000 loan and some free PR proved too much to ignore.

It's a big issue for Baltimore, which has two new bioparks to fill. One particularly thorny issue, according to the Baltimore Business Journal, is getting the city of Baltimore to work as a team with the county. Another key will be in coming up with competitive lease rates for developers in need of lab space.

- read the article in the Baltimore Business Journal

Related Article:
Top Five Regions Targeting Biotech Companies - 2008

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.